OPKO Health Q2 net loss of $101.7M on $309.9M revenue; NGENLA launch, ModeX acquisition

OPKO HEALTH, INC.

2022-Q2 EPS reported -$0.23 revenue$639,111,000

Acquired ModeX for $300M in stock; Dr. Zerhouni appointed President/Vice Chairman, Dr. Nabel Chief Innovation Officer.
Pfizer launched NGENLA in Europe/Japan; OPKO received $85M milestone payment.
Closed GeneDx sale to Sema4 for ~$322M upfront (cash + shares) plus up to $150M milestones.
BRL diagnostics revenue fell to $186.8M from $397.2M; COVID PCR tests dropped to 0.9M from 2.8M.
Net loss includes $71.2M non-cash charge from Sema4 stock decline; operating loss of $10.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.